检验医学与临床2025，Vol.22Issue(7)：998-1002,5.DOI:10.3969/j.issn.1672-9455.2025.07.027
PD-1/PD-L1抑制剂在肺癌合并肺结核患者中的应用与研究进展
Progress in the treatment of PD-1/PD-L1 inhibitors in lung cancer complicated with pulmonary tuberculosis disease
摘要
Abstract
Lung cancer and pulmonary tuberculosis are two common and serious respiratory diseases that pose a serious threat to health.They not only have a certain correlation in their pathogenesis,but also often show a causal relationship in the clinical manifestations of the same patient.For patients with lung cancer complicated with pulmonary tuberculosis,treatment needs to comprehensively consider the mutual influence and personalized status of the two diseases,balance the priority of treatment for the two diseases,and reduce drug interactions and adverse reactions.With the increasing global attention on lung cancer and tuberculosis,programmed cell death factor receptor-1(PD-1)/programmed death factor ligand-1(PD-L1)inhibitors have shown significant efficacy in the treatment of lung cancer,but their application in patients with concomitant tuberculosis still needs attention.Although PD-1/PD-L1 inhibitors are effective in the treatment of lung canc-er,their specific effects and risks in tuberculosis patients are still unclear.At present,there is insufficient un-derstanding of the applicability and safety of PD-1/PD-L1 inhibitors in patients with tuberculosis and lung cancer.Future research should actively explore immunotherapy and personalized management,while strength-ening latent tuberculosis screening and pre immunotherapy risk assessment to provide guidance for improving patient safety and efficacy.关键词
程序性死亡因子受体-1/程序性死亡因子配体-1/抑制剂/肺癌/肺结核Key words
programmed cell death factor receptor-1/programmed death factor ligand-1/inhibitor/lung cancer/pulmonary tuberculosis分类
医药卫生引用本文复制引用
范娜,蒋登蓉,王瑜..PD-1/PD-L1抑制剂在肺癌合并肺结核患者中的应用与研究进展[J].检验医学与临床,2025,22(7):998-1002,5.基金项目
重庆市教育委员会科学技术研究项目(KJQN202300133). （KJQN202300133）
